BOOST: A new pathway with BronchOscopic or Oesophageal ultrasound for lung cancer diagnosis and STaging

A randomised controlled trial of endobronchial ultrasound or endoscopic ultrasound as a first test in the diagnosis and staging of lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN49573946

Enrollment

168

Registered

2008-05-23

Start date

2008-04-07

Completion date

Unknown

Last updated

2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer Cancer Lung cancer

Interventions

Control arm: bronchoscopy, CT guided lung biopsy, PET scan, mediastinoscopy Active arm: endobronchial or endoscopic ultrasound (EUS or EBUS, respectively) Follow-up is

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged greater than 18 years, either sex 2. Consecutive patients suspected of lung cancer on CT scan 3. Written informed consent 4. Able to tolerate fibre-optic bronchoscopy

Exclusion criteria

Exclusion criteria: 1. Evidence of severe or uncontrolled systemic disease that makes it undesirable for the patient to participate in the trial 2. Any disorder making reliable informed consent impossible 3. Patient unlikely to tolerate bronchoscopy 4. Patients with extra-thoracic disease, supraclavicular lymphadenopathy or pleural effusion

Design outcomes

Primary

Measure	Time frame
Time from first outpatient appointment to decision to treat. Information for the endpoints will be collected prospectively as patients go through the diagnostic and staging process and case report forms (CRFs) will be updated weekly. The information will be obtained from multi-disciplinary team meetings (MDTs), patient notes and electronic patient records.	—

Secondary

Measure	Time frame
1. The health care costs of diagnosing and staging lung cancer 2. The number of tests and outpatient visits a patient requires to be diagnosed and staged with lung cancer 3. The proportion of lung cancer patients that are diagnosed and staged with a single test after CT scan 4. The time from first outpatient appointment to treatment 5. The number of futile thoracotomies Information for the endpoints will be collected prospectively as patients go through the diagnostic and staging process and case report forms (CRFs) will be updated weekly. The information will be obtained from multi-disciplinary team meetings (MDTs), patient notes and electronic patient records.	—

Measure

Time frame

1. The health care costs of diagnosing and staging lung cancer 2. The number of tests and outpatient visits a patient requires to be diagnosed and staged with lung cancer 3. The proportion of lung cancer patients that are diagnosed and staged with a single test after CT scan 4. The time from first outpatient appointment to treatment 5. The number of futile thoracotomies Information for the endpoints will be collected prospectively as patients go through the diagnostic and staging process and case report forms (CRFs) will be updated weekly. The information will be obtained from multi-disciplinary team meetings (MDTs), patient notes and electronic patient records.

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026